| Document |
Document Title |
|
WO/2024/079351A1 |
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/080321A1 |
The present invention provides: a compound which is capable of producing a polymer that has excellent alkali durability; a polymer which comprises this compound as a monomer; an electrolyte membrane which uses this polymer and has excell...
|
|
WO/2024/078387A1 |
A substituted 3-fluorobenzenepropanoate compound represented by formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate (such as a hydrate) thereof, a clathrate thereof, a racemate thereof, a co-crys...
|
|
WO/2024/077232A2 |
The present disclosure relates, in part, to immune cell targeted lipid nanoparticle (LNP) compositions, and methods of use thereof for ex vivo delivery of nucleic acid molecules and/or therapeutic agents to a target cell. In certain embo...
|
|
WO/2024/074501A1 |
The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.
|
|
WO/2024/072908A1 |
Provided herein are compounds having one or more cleavable disulfide moieties and one or more hydrophobic tail moieties (HTM) for delivery of one or more therapeutic or diagnostic agents. In some embodiments, the one or more therapeutic ...
|
|
WO/2024/068553A1 |
The present invention relates to tertiary amide compounds of formula (II), or a pharmaceutically acceptable salt thereof, wherein R7 comprises a group X which is -S(=O)2OH, -S(=O)OH or -P(=O)(OH)2- The compounds are capable of solubilizi...
|
|
WO/2024/060641A1 |
The present invention provides a cyclotriarylphosphine ligand represented by general formula (I), and a method for preparing same. The present invention also provides a complex of palladium in coordination with the cyclotriarylphosphine ...
|
|
WO/2024/059745A2 |
A series of novel substituted (hetero)arylmethanamines is described which bind to the N-methyl-D-aspartate receptor. Such compounds have value in various therapeutic indications including, but not limited to, pain, depression, tinnitus, ...
|
|
WO/2024/052923A1 |
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
|
|
WO/2024/054669A2 |
The present disclosure provides compounds according to Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, and XIV used as a component of lipid nanoparticle compositions for the delivery of a biological and/or therapeutic age...
|
|
WO/2024/050352A2 |
The present disclosure provides modified immune cells or precursors thereof comprising chimeric antigen receptors and surface-bound, biologically inert molecules. Also included are methods of preparing said modified immune cells and meth...
|
|
WO/2024/049979A2 |
Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.
|
|
WO/2024/050062A1 |
The present disclosure is concerned with substituted aminopiperazine compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in the treatment of antimicrobial infections such a...
|
|
WO/2024/043334A1 |
The present invention addresses the problem of providing a compound and pharmaceutical composition that possesses inhibitory activity against the drug efflux pumps of drug-resistant bacteria and, when used in combination with another dru...
|
|
WO/2024/040496A1 |
Disclosed are an antiviral compound, and a preparation method therefor and a use thereof, particularly an anti-coronavirus compound capable of being used as a PLpro inhibitor, and a preparation method therefor and a use thereof. The comp...
|
|
WO/2024/044147A1 |
Provided herein are methods for purifying an ionizable amino lipid (IAL) composition comprising impurities that may react with polynucleotides, such as mRNA. Methods for purifying IAL compositions comprise one or more scavenging-removal ...
|
|
WO/2024/037422A1 |
The present disclosure relates to crystalline forms of (E) -N- ( (1R, 2R) -1- (3-chloro-4-cyclopropoxyphenyl) -1-hydroxy-3- (pyrrolidin-1-yl) propan-2-yl) -2- (6-chloronaphthalen-2-yl) -2- (hydroxyimino) acetamide, the method of preparin...
|
|
WO/2024/035783A2 |
Lipid nanoparticle compositions (LNPs), methods for preparing the LNPs, methods of using the same, including, but not limited to, for treatment of certain diseases and disorders, including, but not limited to liver disorders, kits for th...
|
|
WO/2024/033667A1 |
The present invention relates to visible light sensitive photoremovable protecting groups and their parent compounds X including a xanthene, xanthenium or related cores, represented by formula (Xa): (Xa) wherein the substituents are as d...
|
|
WO/2024/027789A1 |
Disclosed are a cationic lipid compound as represented by formula (I) and composition for nucleic acid delivery, and a use. Also disclosed are a use of nano-lipid particles using said compound as a key component in the aspect of nucleic ...
|
|
WO/2024/028808A1 |
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...
|
|
WO/2024/031051A1 |
Provided herein are ionizable lipids, compositions comprising the ionizable lipids, and methods of making and using the same. The ionizable lipids provided herein can be formulated in lipid compositions for the delivery of macromolecules...
|
|
WO/2024/026479A2 |
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
|
|
WO/2024/023287A1 |
The present invention relates to a compound of general formula (I). The invention further relates to the compounds of the invention as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological...
|
|
WO/2024/026486A2 |
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
|
|
WO/2024/026481A2 |
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
|
|
WO/2024/026483A2 |
The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
|
|
WO/2024/019936A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2024/011414A1 |
Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...
|
|
WO/2024/012568A1 |
The invention relates to a key intermediate for preparing glucopyranosyl derivatives and preparation method thereof, the glucopyranosyl derivatives are sodium-dependent glucose transporter (SGLT) inhibitors. Specifically, the key interme...
|
|
WO/2024/011415A1 |
Disclosed in the present invention is a method for preparing an o-iodophenyl compound, wherein an iodobenzene compound and an amide compound as raw materials are reacted in the presence of sodium hydride or n-butyllithium and a solvent t...
|
|
WO/2023/280638A9 |
The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
|
|
WO/2024/009324A1 |
The present invention provides the novel prodrugs of cannabidio-type phytocannabinoids having the general Formula A and its process thereof, where one or both the hydroxyl groups are attached to the other counter parts through ester bond...
|
|
WO/2024/001995A1 |
The present invention relates to the technical field of drug synthesis, in particular to a lifitegrast morpholine salt, a method for preparing same, and use thereof. The lifitegrast morpholine salt provided by the present invention can b...
|
|
WO/2024/001487A1 |
The present invention relates to the technical field of green, clean and efficient catalysis, and in particular, to a method for synthesizing a cyclic carbonate from carbon dioxide and an epoxy compound by means of a catalytic reaction a...
|
|
WO/2023/250197A2 |
The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, st...
|
|
WO/2023/246218A1 |
Provided are an ionizable lipid for nucleic acid delivery and a composition thereof, which belong to the field of pharmaceutical chemistry. Provided are a compound represented by formula I and use of the compound as a nucleic acid delive...
|
|
WO/2023/246074A1 |
Provided in the present invention are a cationic lipid compound used for nucleic acid delivery, a composition and a use. The compound is as shown in the following formula (I). Further provided in the present invention are the use of the ...
|
|
WO/2023/246747A1 |
Provided in the present invention are a cationic lipid compound and a composition for delivery of a nucleic acid, and the use. The compound is represented by the following formula (I). Further provided in the present invention are the us...
|
|
WO/2023/244630A1 |
Cleaning booster for cleaning dirty laundry is provided, wherein the cleaning booster is of formula (I) wherein E1 and E2 are independently selected from a divalent linking group having 1 to 4 carbon atoms; and wherein each R1 is indepen...
|
|
WO/2023/245015A2 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
|
|
WO/2023/243522A1 |
The purpose of the present invention is to provide a method for producing an aromatic compound, wherein a cross-coupling reaction by means of a mechanochemical process is carried out in a state where a solvent is not substantially contai...
|
|
WO/2023/241140A1 |
The present invention relates to the technical field of biological medicine, particularly to use of a class of substituted diaryl compounds in the preparation of anti-inflammatory drugs. The compounds have a structure represented by form...
|
|
WO/2023/242597A1 |
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
|
|
WO/2023/244631A1 |
A liquid laundry detergent is provided, comprising: liquid carrier; cleaning surfactant; and cleaning booster of formula (I) wherein E1 and E2 are independently selected from a divalent linking group having 1 to 4 carbon atoms; and where...
|
|
WO/2023/237729A1 |
A process for making a substantially nitrosamine-free, substantially peroxide-free, substantially colorless amine oxide solution comprises reacting a tertiary amine capable of forming an amine oxide with a less than stoichiometric amount...
|
|
WO/2023/236809A1 |
The present invention belongs to the technical field of anti-inflammatory drugs. Disclosed are a 2,6-dibenzylidene cyclohexanone oxime compound, a method for preparing same, and use thereof. According to the present invention, a structur...
|
|
WO/2023/235976A1 |
A polycation carrier particle obtained by the polymerization of a multiacrylate monomer with one or more hydrophilic monomers to form crosslinks. The polycation carrier particle has a net positive electric charge. The multiacrylate monom...
|
